Processa Pharmaceuticals (PCSA) Competitors $0.24 +0.00 (+0.95%) Closing price 04:00 PM EasternExtended Trading$0.24 +0.00 (+0.66%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PCSA vs. APM, KLTO, DRMA, TTNP, TCRT, CDT, EVOK, ONCO, CMND, and SONNShould you be buying Processa Pharmaceuticals stock or one of its competitors? The main competitors of Processa Pharmaceuticals include Aptorum Group (APM), Klotho Neurosciences (KLTO), Dermata Therapeutics (DRMA), Titan Pharmaceuticals (TTNP), Alaunos Therapeutics (TCRT), Conduit Pharmaceuticals (CDT), Evoke Pharma (EVOK), Onconetix (ONCO), Clearmind Medicine (CMND), and Sonnet BioTherapeutics (SONN). These companies are all part of the "pharmaceutical products" industry. Processa Pharmaceuticals vs. Aptorum Group Klotho Neurosciences Dermata Therapeutics Titan Pharmaceuticals Alaunos Therapeutics Conduit Pharmaceuticals Evoke Pharma Onconetix Clearmind Medicine Sonnet BioTherapeutics Processa Pharmaceuticals (NASDAQ:PCSA) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends. Do insiders and institutionals hold more shares of PCSA or APM? 91.9% of Processa Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 13.0% of Processa Pharmaceuticals shares are owned by company insiders. Comparatively, 64.0% of Aptorum Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer PCSA or APM? Processa Pharmaceuticals currently has a consensus price target of $6.00, indicating a potential upside of 2,365.08%. Given Processa Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Processa Pharmaceuticals is more favorable than Aptorum Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Processa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aptorum Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer PCSA or APM? Aptorum Group received 26 more outperform votes than Processa Pharmaceuticals when rated by MarketBeat users. Likewise, 68.33% of users gave Aptorum Group an outperform vote while only 60.00% of users gave Processa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformProcessa PharmaceuticalsOutperform Votes1560.00% Underperform Votes1040.00% Aptorum GroupOutperform Votes4168.33% Underperform Votes1931.67% Which has better earnings and valuation, PCSA or APM? Aptorum Group has higher revenue and earnings than Processa Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProcessa PharmaceuticalsN/AN/A-$11.12M-$3.08-0.08Aptorum Group$430K10.70-$2.83MN/AN/A Is PCSA or APM more profitable? Aptorum Group's return on equity of 0.00% beat Processa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Processa PharmaceuticalsN/A -195.21% -163.06% Aptorum Group N/A N/A N/A Does the media prefer PCSA or APM? In the previous week, Processa Pharmaceuticals' average media sentiment score of 0.00 equaled Aptorum Group'saverage media sentiment score. Company Overall Sentiment Processa Pharmaceuticals Neutral Aptorum Group Neutral Which has more risk and volatility, PCSA or APM? Processa Pharmaceuticals has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Aptorum Group has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500. SummaryAptorum Group beats Processa Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get Processa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCSA vs. The Competition Export to ExcelMetricProcessa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.89M$6.49B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-0.079.1826.8919.71Price / SalesN/A252.26386.75120.59Price / CashN/A65.8538.2534.62Price / Book0.066.456.774.50Net Income-$11.12M$144.21M$3.23B$248.22M7 Day Performance-1.46%2.46%1.82%0.56%1 Month Performance10.34%4.59%11.12%13.17%1 Year Performance-86.77%-2.68%17.09%7.30% Processa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCSAProcessa Pharmaceuticals3.0697 of 5 stars$0.24+1.0%$6.00+2,365.1%-87.3%$2.89MN/A-0.0720APMAptorum Group0.354 of 5 stars$0.93+7.9%N/A-76.6%$4.97M$430,000.000.0030Positive NewsKLTOKlotho NeurosciencesN/A$0.17+5.0%N/AN/A$4.89MN/A0.00N/APositive NewsEarnings ReportHigh Trading VolumeDRMADermata Therapeutics1.3163 of 5 stars$0.79-2.0%$6.00+655.7%-77.5%$4.79MN/A-0.058Positive NewsAnalyst ForecastTTNPTitan Pharmaceuticals0.19 of 5 stars$5.23+2.8%N/A-31.7%$4.78M$180,000.00-1.0010Analyst ForecastGap UpTCRTAlaunos Therapeutics1.1132 of 5 stars$2.85flatN/A-76.3%$4.67M$10,000.000.0040Positive NewsEarnings ReportGap DownCDTConduit Pharmaceuticals0.7041 of 5 stars$0.41+2.3%N/A-99.9%$4.64MN/A-0.013News CoverageEarnings ReportStock SplitEVOKEvoke Pharma0.1066 of 5 stars$3.11-1.1%N/A-36.3%$4.64M$10.25M-0.284Negative NewsGap UpONCOOnconetix0.0628 of 5 stars$0.07-2.8%N/A-98.4%$4.52M$1.87M0.0012News CoveragePositive NewsGap UpCMNDClearmind Medicine0.1308 of 5 stars$0.99+2.2%N/A-16.7%$4.21MN/A-0.53N/ASONNSonnet BioTherapeutics2.0584 of 5 stars$1.33+3.9%$20.00+1,403.8%-27.3%$4.08M$1M0.0010 Related Companies and Tools Related Companies Aptorum Group Alternatives Klotho Neurosciences Alternatives Dermata Therapeutics Alternatives Titan Pharmaceuticals Alternatives Alaunos Therapeutics Alternatives Conduit Pharmaceuticals Alternatives Evoke Pharma Alternatives Onconetix Alternatives Clearmind Medicine Alternatives Sonnet BioTherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCSA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Processa Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Processa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PCSA Stock Free PCSA Stock Alerts